TY - JOUR
T1 - New Perspectives on Antimicrobial Agents
T2 - Long-Acting Lipoglycopeptides
AU - Tran, Truc T.
AU - Villegas, Sara Gomez
AU - Aitken, Samuel L.
AU - Butler-Wu, Susan M.
AU - Soriano, Alex
AU - Werth, Brian J.
AU - Munita, Jose M.
N1 - Funding Information:
Copyright © 2022 American Society for Microbiology. All Rights Reserved. Address correspondence to Jose M. Munita, josemunita@udd.cl, or Truc T. Tran, tttran4@houstonmethodist.org. The authors declare a conflict of interest. B.J.W. is supported by National Institutes of Allergy and Infectious Diseases grant R01AI136979. J.M.M. reports grant from Pfizer outside of submitted work. [This article was published on 27 April 2022 with incomplete affiliation information for Truc T. Tran and Sara Gomez Villegas. The missing affiliation was added in the current version, posted on 9 May 2022.] Published 27 April 2022
Publisher Copyright:
© 2022 American Society for Microbiology.
PY - 2022/6
Y1 - 2022/6
N2 - The long-acting lipoglycopeptides (LGPs) dalbavancin and oritavancin are semisynthetic antimicrobials with broad and potent activity against Gram-positive bacterial pathogens. While they are approved by the Food and Drug Administration for acute bacterial skin and soft tissue infections, their pharmacological properties suggest a potential role of these agents for the treatment of deep-seated and severe infections, such as bloodstream and bone and joint infections. The use of these antimicrobials is particularly appealing when prolonged therapy, early discharge, and avoidance of long-term intravascular catheter access are desirable or when multidrug-resistant bacteria are suspected. This review describes the current evidence for the use of oritavancin and dalbavancin in the treatment of invasive infections, as well as the hurdles that are preventing their optimal use. Moreover, this review discusses the current knowledge gaps that need to be filled to understand the potential role of LGPs in highly needed clinical scenarios and the ongoing clinical studies that aim to address these voids in the upcoming years.
AB - The long-acting lipoglycopeptides (LGPs) dalbavancin and oritavancin are semisynthetic antimicrobials with broad and potent activity against Gram-positive bacterial pathogens. While they are approved by the Food and Drug Administration for acute bacterial skin and soft tissue infections, their pharmacological properties suggest a potential role of these agents for the treatment of deep-seated and severe infections, such as bloodstream and bone and joint infections. The use of these antimicrobials is particularly appealing when prolonged therapy, early discharge, and avoidance of long-term intravascular catheter access are desirable or when multidrug-resistant bacteria are suspected. This review describes the current evidence for the use of oritavancin and dalbavancin in the treatment of invasive infections, as well as the hurdles that are preventing their optimal use. Moreover, this review discusses the current knowledge gaps that need to be filled to understand the potential role of LGPs in highly needed clinical scenarios and the ongoing clinical studies that aim to address these voids in the upcoming years.
KW - dalbavancin
KW - lipoglycopeptide
KW - oritavancin
KW - Anti-Infective Agents/pharmacology
KW - Humans
KW - Lipoglycopeptides/therapeutic use
KW - Glycopeptides/chemistry
KW - Gram-Positive Bacterial Infections/drug therapy
KW - Anti-Bacterial Agents/pharmacology
KW - Teicoplanin/pharmacology
UR - http://www.scopus.com/inward/record.url?scp=85132455837&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132455837&partnerID=8YFLogxK
U2 - 10.1128/aac.02614-20
DO - 10.1128/aac.02614-20
M3 - Review article
C2 - 35475634
AN - SCOPUS:85132455837
SN - 0066-4804
VL - 66
SP - e0261420
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 6
ER -